Lucidin from <i>Rubia cordifolia</i> Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins

<b>Background:</b> Breast cancer remains a significant global health concern, with approximately 2.3 million diagnosed cases and 670,000 deaths annually. Current targeted therapies face challenges such as resistance and adverse side effects. This study aimed to explore natural compounds...

全面介紹

書目詳細資料

發表在:	Pharmaceuticals
Main Authors:	Akram Ahmed Aloqbi, Hadil Alahdal, Amany I. Alqosaibi, Mashael M. Alnamshan, Ibtesam S. Al-Dhuayan, Ahood A. Al-Eidan, Hind A. S. Alzahrani, Nouf K. ALaqeel, Fatmah Hazza Alsharif, Abeer Al Tuwaijri
格式:	Article
語言:	英语
出版:	MDPI AG 2025-01-01
主題:	breast cancer multitargeted therapy Lucidin WaterMap computations molecular dynamics simulations
在線閱讀:	https://www.mdpi.com/1424-8247/18/1/68